SoftOx Solutions AS: New Share Capital

Reference is made to the stock exchange release from SoftOx Solutions AS (the "Company") on 9 June 2026 regarding the board resolution to increase the share capital by carrying out a private placement of NOK 6 029 468 under the financing facility with the investment fund Long State Investments Limited (“Long State”).

The new share capital, following completion of the private placement, has today been registered with the Norwegian Register of Business Enterprises.

The new share capital of the Company is NOK 52 035 950.34 divided into 2 601 797 517 shares, each with a par value of NOK 0.02.

For more information on the financing facility, please see the Company's stock exchange release dated 14 September 2025.

For further information, please contact: Ulrik Spork, COB Soft Solutions AS, +45 31 38 83 87 Ingrid Juven, CFO SoftOx Solutions AS, +47 918 76 165 Mail: ir@soft-ox.com

About SoftOx Solutions AS: SoftOx Solutions AS (ticker: SOFTX) is a clinical-stage pharmaceutical company developing SIS (SoftOx Inhalation Solution), a novel inhaled anti-infective therapy for the treatment of respiratory infections in the airways and lungs. The Company is listed on Euronext Growth Oslo.